why choose us

First received: May 05, 2024

Clinical Trial: First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Primary Central Nervous System Lymphoma

Study Type: INTERVENTIONAL


Official Title: Exploration of the Efficacy and Safety of Orelabrutinib Combined With Rituximab and Methotrexate (ORM Regimen) in the First-line Treatment of Primary Central Nervous System Lymphoma

Brief Summary: Exploring the efficacy and safety of first-line treatment of primary central nervous system lymphoma with the combination of orelabrutinib, rituximab and methotrexate (ORM regimen).

Read more